Bausch Health Companies Inc. Common Stock (NY:BHC)

5.770 -0.160 (-2.70%)

Delayed Quote Updated: 10:24 AM EDT, Oct 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Bausch Health Companies Inc. Common Stock

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

Bausch Health Crashes On Unexpected Loss As Bausch & Lomb Starts Trading ↗

May 10, 2022

The new Bausch & Lomb started trading Tuesday as its former parent company crashed.

Via Investor's Business Daily

Bausch Health Companies: Q1 Earnings Insights ↗

May 10, 2022

Bausch Health Companies (NYSE:BHC) reported its Q1 earnings results on Tuesday, May 10, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

RBC Capital: What To Expect When Bausch Health Companies Reports Q1 Tomorrow ↗

May 09, 2022

RBC Capital Markets expects Bausch Health Companies Inc (NYSE: BHC) Q1 FY22 revenue of $2.02 billion (previous $2.04 billion; consensus $2.05 billion) and adjusted EBITDA of $799 million (previous $816...

Via Benzinga

Earnings Preview: Bausch Health Companies ↗

May 09, 2022

Bausch Health Companies (NYSE:BHC) is set to give its latest quarterly earnings report on Tuesday, 2022-05-10. Here's what investors need to know before the announcement. Analysts estimate that Bausch...

Via Benzinga

The Week Ahead In Biotech (May 8-14): Bausch Health Headlines Smid-Cap Earnings, Veru's Pre-EUA Meeting, Conference Presentations And More ↗

May 09, 2022

Biotech stocks declined yet again in the week ending May 6, dragged lower by macroeconomic concerns following the Federal Reserve's 50-basis-point rate hike. The iShares Biotechnology ETF (NASDAQ:...

Via Benzinga

Closely Watched Bausch + Lomb IPO Priced Below Expectations ↗

May 06, 2022

Via Benzinga

Opening Day: Bausch + Lomb Pops In Public Debut ↗

May 07, 2022

Shares of Bausch + Lomb rose over 11% to end its first trading day at $20. This was the second biggest IPO of the year. Bausch + Lomb opened at $18.50 after having priced its initial public offering at...

Via Talk Markets

BLCO Stock: 7 Things to Know About the Bausch + Lomb IPO Today ↗

May 06, 2022

Here's what investors in Bausch + Lomb may want to know about the highly anticipated BLCO stock IPO, which took place today.

Via InvestorPlace

Morning Brief: Top Financial Stories Dominating on Friday, May 6 ↗

May 06, 2022

Reuters IHG Hotels & Resorts On Way To Recovery As Travel Booms

Via Benzinga

Why Cramer Recommends Buying Marvell Technology ↗

May 05, 2022

On CNBC’s "Mad Money Lightning Round," Jim Cramer said Accenture plc (NYSE: ACN) had a great quarter. He recommended buying the stock.

Via Benzinga

BLCO Stock IPO: When Does Bausch + Lomb Go Public? What Is the Bausch + Lomb IPO Price Range? ↗

May 02, 2022

Here's what investors may want to know about the upcoming BLCO stock IPO, as Bausch + Lomb is split off from its parent company this week.

Via InvestorPlace

The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More ↗

May 02, 2022

Biotech stocks posted weekly declines yet again in the week ending April 29, taking cues from the weak broader market sentiment. Big pharma earnings, clinical readouts and pipeline updates moved stocks...

Via Benzinga

Opening Day: Tenon Medical Shares Soar In Market Debut ↗

April 30, 2022

Shares of Tenon Medical soared in their market debut on Wednesday, opening at $22.05 after the medical-device company had priced its IPO at $5 per share. Meanwhile, Belite Bio opened on April 29 at...

Via Talk Markets

Jim Cramer Says This Stock Is Still Terrific ↗

April 25, 2022

On CNBC’s "Mad Money Lightning Round," Jim Cramer said Tredegar Corporation (NYSE: TG) was terrific at the time it became public, and it is terrific now also.

Via Benzinga

IPO Market Stalls With Potential Blockbuster Deals Waiting For Rebound ↗

April 07, 2022

Though IPOs in the first quarter plunged to their lowest level in six years, many companies are in the pipeline ready to go public.

Via Investor's Business Daily

Opening Day: AN2 Therapeutics Rises In Public Debut After Upsized IPO ↗

March 26, 2022

Shares of AN2 Therapeutics rose over 15% in its trading debut on Friday following an upsized initial public offering. This was only the second initial public offering this month, as the IPO market...

Via Talk Markets

Opening Day: Cannabis Name Akanda Opens Way Above IPO Pricing, Pulls Back ↗

March 19, 2022

On its first trading day, Akanda fell about 65% from its opening price of $30, though that opening price was nearly eight-times its IPO price of $4. Meanwhile, startup Knock scrapped its plans to go...

Via Talk Markets

Opening Day: New Stock Offerings Slump To Lowest Number In A Decade ↗

March 05, 2022

It was another slow week for IPOs in the U.S. New stock offerings slumped to the lowest number in over a decade last month amid the war in Ukraine and as rising borrowing costs sent share prices...

Via Talk Markets

Bausch Health Companies Q4 Sales, FY22 Outlook Lag Wall Street View ↗

February 23, 2022

Bausch Health Companies Inc (NYSE: BHC) has reported Q4 revenues of $2.19 billion, down 1% Y/Y, missing the consensus of $2.80 billion. Excluding the impact of foreign...

Via Benzinga

Bausch Health Companies: Q4 Earnings Insights ↗

February 23, 2022

Bausch Health Companies (NYSE:BHC) reported its Q4 earnings results on Wednesday, February 23, 2022 at 07:00 AM. Here's what investors need to know about the...

Via Benzinga

The Daily Biotech Pulse: Kodiak Sinks On Adverse Study Outcome, Marinus Flags Delay In Clinical Trial, Mainz Biomed Gains On Positive Regulatory Development ↗

February 23, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Kodiak's Wet AMD Treatment KSI-301 Did Not Meet Primary Endpoint In Phase...

Via Benzinga

Recap: Bausch Health Companies Q4 Earnings ↗

February 23, 2022

Bausch Health Companies (NYSE:BHC) reported its Q4 earnings results on Wednesday, February 23, 2022 at 07:00 AM. Here's what investors need to know about the...

Via Benzinga

Preview: Bausch Health Companies's Earnings ↗

February 22, 2022

Bausch Health Companies (NYSE:BHC) is set to give its latest quarterly earnings report on Wednesday, 2022-02-23. Here's what investors need to know before the announcement....

Via Benzinga

Opening Day: Nutraceutical Seller Smart For Life Plunges Following IPO ↗

February 19, 2022

Shares of Smart for Life plunged about 75% following its initial public offering on the Nasdaq. Blue Water Vaccines opened at $50 after having priced its initial public offering of 2.22 million shares...

Via Talk Markets

The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow ↗

February 20, 2022

Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front...

Via Benzinga

Why The Justice Department Is Going After Short Sellers ↗

February 17, 2022

Federal prosecutors are reportedly ramping up a probe into the activities of short sellers, serving subpoenas and seizing hard drives and mobile phones of prominent "activist...

Via Benzinga

Two Insider Moonshots Rising on Sudden Buying ↗

February 10, 2022

Biotech insiders are among the most important investors to pay close attention to. Here are two that show good signs for the future.

Via InvestorPlace

Jim Cramer Buys The Dip In Salesforce, Marvell And This Health Stock ↗

January 21, 2022

With the markets falling further into correction territory, Jim Cramer decided to start adding to some of the positions in hi...

Via Benzinga

Bausch Health's Eye-Care Spin-Off Entity Files For $100M IPO ↗

January 14, 2022

Bausch & Lomb Corp filed S-1 for its initial public offering, nearly 1.5 years after its parent company, Bausch Health Companies Inc (NYSE: BHC) said it would...

Via Benzinga

The Daily Biotech Pulse: Bausch Files For Eye Health Unit IPO, LumiraDx Antigen Test Can Detect Omicron, Molecular Partners Discloses Fund Stake ↗

January 14, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Corvus Says Chinese Angel Pharma Starts Phase 1/2 Blood Cancer Study Corvus...

Via Benzinga

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.